Andrew Brackin

Partner at Gradient Ventures

San Francisco, California

Overview

Andrew Brackin is a Partner at Gradient Ventures and Co-Founder at Vial, with a background in entrepreneurship, digital marketing, and online advertising. He has successfully co-founded Vial and led growth initiatives at Newfront, showcasing expertise in generative tech/AI sectors and the San Francisco Bay Area startup scene.

Work Experience

Gradient

Partner
2024 - Current
Leading early rounds at Gradient, a seed fund focused on applied AI investments. Partner to: - Enzo (enzo.health): AI for home health - Hostie (hostie.ai): AI for restaurants - Paladin (paladindrones.io): AI-enabled response for public safety - Forge (forgehq.com): Automated refunds on tariffs & duties - Vera (vera-health.ai): AI for clinical decision making Work closely with: RadAI, Heyday Health, Patlytics, Vault, Zowie, Axle, and others.

Gradient is a seed fund that invests in founders developing AI technologies.

gradient.com

Vial

Co-Founder & COO
2020 - 2023
Co-founded Vial to run faster clinical trials with technology. Led go-to-market, raised $100M+ in capital from General Catalyst, Buckley Ventures, Byers Capital and Box Group.

Scalable biotech advancing clinical programs with cost-effective trials and computationally designed therapeutics.

Raised $101,000,000.00 from Patrick Hsu, Connor Zwick, Gordon Wintrob, Josh Buckley, Buckley Ventures, General Catalyst, Byers Capital and Spike Lipkin.

vial.com

Newfront

Founding Team, Head of Growth
2018 - 2020
One of the first employees at Newfront (backed by Y Combinator, Founders Fund, and Meritech). A tech-enabled insurance brokerage. Valued at $2.2BN in 2022 merger.

Newfront is an insurance company that provides risk control, risk analytics, and benchmarking claims advocacy.

Raised $310,000,000.00 from Y Combinator, Bloomberg Beta, Altai Ventures, Susa Ventures, B Capital, Vetamer, Founders Fund, Tony Xu, PruVen Capital and Stack Capital.

newfront.com